Regeneron Pharmaceuticals Stock Forecast, Price & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 21.6% and is now trading at $565.00.
View which stocks have been most impacted by COVID-19.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $5.59 by $1.57. The biopharmaceutical company earned $1.95 billion during the quarter, compared to analysts' expectations of $1.74 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The company's quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.02 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its board has approved a share repurchase program on Tuesday, November 5th 2019, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 2.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

27 Wall Street analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $592.78 in the next year. This suggests a possible upside of 4.9% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a decline in short interest in August. As of August 14th, there was short interest totaling 1,600,000 shares, a decline of 15.3% from the July 30th total of 1,890,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 1.4 days. Approximately 1.6% of the shares of the stock are sold short.
View Regeneron Pharmaceuticals' Short Interest.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Netflix (NFLX), Gilead Sciences (GILD), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Intel (INTC).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (11.71%), BlackRock Inc. (8.90%), Vanguard Group Inc. (7.13%), Nuveen Asset Management LLC (1.60%), California Public Employees Retirement System (0.76%) and Bank of New York Mellon Corp (0.70%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Candriam Luxembourg S.C.A., Perceptive Advisors LLC, LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, Advisor Group Holdings Inc., and NN Investment Partners Holdings N.V.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Vanguard Group Inc., California Public Employees Retirement System, Nuveen Asset Management LLC, APG Asset Management N.V., Swiss National Bank, and Bank of New York Mellon Corp.
View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $565.00.

Regeneron Pharmaceuticals has a market capitalization of $60.11 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]